Wall Street has a new favorite subplot in the diabetes and obesity saga: a three-act story where Sanofi (SNY) shores up the autoimmune front, Modular Medical (MODD) quietly rewires insulin delivery, and the GLP‑1 heavyweights audition next‑gen obesity drugs on the ADA…
For millions of people living with diabetes, “advanced technology” still means a pocket full of syringes and a mental spreadsheet of carbs, units, and timing. Into that world steps Modular Medical’s (NASDAQ: MODD) Pivot Insulin Delivery System, a tubeless insulin patch pump…
Modular Medical’s (NASDAQ: MODD) Pivot insulin delivery system reads like a classic Wall Street story: a veteran founder, a large underserved market, and a product designed to make a complex therapy finally feel simple.
The Engineer Who Refused to Over-Engineer
Paul…
Modular Medical’s (NASDAQ: MODD) latest capital raise seems to read less like a distress flare and more like a carefully aimed flare gun over the diabetes device market, signaling that the small-cap insurgent still plans to play big-league offense in insulin delivery…
Modular Medical’s (NASDAQ: MODD) Pivot insulin delivery system is quietly building a credible bull case that now extends beyond regulatory momentum and leadership credentials into hard operational execution. With the company achieving a key manufacturing milestone for its Pivot tubeless insulin patch…
